Resveratrol inhibits mTOR signaling by targeting DEPTOR

References

• Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 2010; 131:261 - 269
   PubMed Web of Science ®Google Scholar
• Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127:1109 - 1122
   PubMed Web of Science ®Google Scholar
• Chen H, Yang Z, Gibbs D, Yang X, Hau V, Zhao P, et al. Association of HTRA1 polymorphism and bilaterality in advanced age-related macular degeneration. Vision Res 2008; 48:690 - 694
   PubMed Web of Science ®Google Scholar
• Acharya SH, Philip S, Viswanath AK, Boroujerdi M, Waugh NR, Pearson DW. Glycaemic control and body mass index in late-adolescents and young adults with Type 1 diabetes mellitus: a population-based study. Diabet Med 2008; 25:360 - 364
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337 - 342
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471 - 484
   PubMed Web of Science ®Google Scholar
• Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007; 17:666 - 681
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457 - 468
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122:3589 - 3594
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9 - 22
   PubMed Web of Science ®Google Scholar
• Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430:686 - 689
   PubMed Web of Science ®Google Scholar
• Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005; 37:349 - 350
   PubMed Web of Science ®Google Scholar
• Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004; 141:997 - 1005
   PubMed Web of Science ®Google Scholar
• Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59:554 - 563
   PubMed Web of Science ®Google Scholar
• Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 2008; 283:24194 - 24201
   PubMed Web of Science ®Google Scholar
• Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 2009; 8:25 - 33
   PubMedGoogle Scholar
• Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 2010; 285:36387 - 36394
   PubMed Web of Science ®Google Scholar
• Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide-3-kinase inhibitor. Biochem J 2007; 406:511 - 518
   PubMed Web of Science ®Google Scholar
• Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 1998; 95:7772 - 7777
   PubMed Web of Science ®Google Scholar
• Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b and phosphatidylinositol-3-kinase in GLUT1 mRNA translation. J Biol Chem 1999; 274:33085 - 33091
   PubMed Web of Science ®Google Scholar
• Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11:1457 - 1466
   PubMed Web of Science ®Google Scholar
• Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 2003; 5:566 - 571
   PubMed Web of Science ®Google Scholar
• Proud CG. Dynamic balancing: DEPTOR tips the scales. J Mol Cell Biol 2009; 1:61 - 63
   PubMed Web of Science ®Google Scholar
• Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137:873 - 886
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213 - 223
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol-3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489 - 501
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35:148 - 159
   PubMed Web of Science ®Google Scholar
• Harris TE, Lawrence JC Jr. TOR signaling. Sci STKE 2003; 15
   Google Scholar
• Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/ mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022 - 8030
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125:733 - 747
   PubMed Web of Science ®Google Scholar
• Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promises. Curr Opin Pharmacol 2008; 8:393 - 412
   PubMed Web of Science ®Google Scholar
• Lempiainen H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J 2009; 28:3067 - 3073
   PubMed Web of Science ®Google Scholar